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Summary We report the use of the steroidal aromatase inhibitor, 4-hydroxyandrostenedione (4-OHA, CGP
32349), in the management of patients with advanced, hormone resistant, prostatic cancer. Eighteen of 25
patients (72%) showed a subjective response, mainly in the form of pain relief and increased performance.
There were no objective improvements. A tumour flare occurred in 17/25 (68%). Detailed endocrine studies
were performed during treatment. These showed that suppression of serum oestradiol levels occurred in 19/25
(76%) of patients during treatment with 4-OHA. Serum levels of androstenedione increased in 9/14 patients
(64%). Concentration of serum testosterone and 5 alpha-dihydrotestosterone were elevated in 3/14 (21%) and
2/11 (18%) patients respectively. There appeared to be no correlation between response or tumour flare and
changes in steroid levels during treatment with 4-OHA.
The mechanism of action of 4-OHA in palliating patients with advanced prostatic cancer remains obscure.
4-OHA or its metabolites may be acting on metastatic bone metabolism via effects on oestrogen related
osteoclastic and osteoblastic activity. Further investigation of the effects of aromatase inhibitors on prostatic
biology, and bone metabolism in patients with metastatic prostate cancer, would appear worthwhile.
The management of patients with advanced, hormone resis-
tant prostatic cancer is difficult and consists mainly of pallia-
tion of symptoms (Lancet, 1980). The life expectancy of this
group of patients is limited (Parker et al., 1985). Since 1987,
we have investigated the possible place of aromatase
inhibitors in the management of advanced prostate cancer.
Aromatase (oestrogen synthetase) mediates the conversion of
androgens to oestrogens and is a key enzyme in the
steroidogenic pathway from cholesterol to oestrogens. Inhibi-
tion of aromatisation will not cause depletion of steroids
more proximal in the steroidogenic pathway as it is the last
reaction in oestrogen production (Brodie et al., 1977). Wor-
gul et al. (1983) first suggested that aromatase inhibition may
be of benefit in patients with advanced hormone resistant
prostatic cancer. This followed observations during the use of
aminoglutethimide (Ag) in such patients where significant
subjective response were observed (Robinson et al., 1980).
Endocrine studies subsequently showed that the clinical effect
ofAg was not attributable to androgen suppression (Dowsett
et al., 1988). Ag is a potent aromatase inhibitor (Brodie et
al., 1981a) and it was therefore considered possible that this
may be its mode of action. Ag has significant central side
effects limiting its use. A more selective inhibitor was
therefore needed to test this hypothesis.
We have previously reported our preliminary experience
using the selective steroidal aromatase inhibitor (4-hydroxy-
androstendione (4-OHA, CGP 32349) in the palliation of
patients with advanced hormone resistant prostatic cancer
(Shearer et al., 1990). A significant proportion (63%) gained
benefit, mainly in the form of pain relief. However, the
mechanism of action of an aromatase inhibitor in such
patients remained obscure. Oestradiol suppression was
observed in five out of eight patients in which it was
measured. A tumour 'flare' was observed in 31% of the
patients observed. This was thought to possibly represent a
biological response to aromatase inhibition although the
cause of the flare was unknown.
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To investigate further the effects of aromatase inhibition in
advanced prostatic cancer we have evaluated 4-OHA in 30
patients with advanced prostatic cancer who had relapsed
following castration and other palliative therapies. Detailed
endocrine studies were made to establish the steroid changes
occurring during treatment.
Patients and methods
Inclusion criteria
Thirty patients were entered on a protocol, approved by the
Medical Ethics Committee at St Georges Hospital and the
Royal Marsden Hospital, London, to investigate the use of
the aromatase inhibitor, 4-OHA, in advanced prostatic
cancer. All patients had histologically proven carcinoma of
the prostate with severe bone pain associated with metastases
proven on bone scan. No patient entered the study within 6
weeks of any radiotherapy or endocrine treatment. They were
all deemed to have responded to previous primary hormone
manipulation either in the form of orchidectomy or LHRH
administration. The majority had received palliative radio-
therapy or other treatments. All were asked to give informed
written consent prior to participation in the study.
Exclusion criteria
Patients considered to be a poor medical risk due to non-
malignant disease or uncontrolled infection, or to have a life
expectancy of less than 3 months, a known current malig-
nancy at another site or have a performance status of less
than 9 on the Eastern Cooperative Oncology Group (ECOG)
scale (see text) were excluded from the study.
Assessment
All patients were clinically staged at entry into the study and
at 3 and 6 months on treatment. Staging was performed
using UICC, T and M criteria. Primary tumour size was
assessed by trans-rectal ultrasound using a Bruel and Kjaer
machine. Metastases were assessed by bone scan and radio-
graphs. Haematological and biochemical investigations were
performed at monthly clinical assessments as follows: haemo-
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globin, total red cell count, platelets and white cell count;
liver function, blood sugar, acid and alkaline phosphatases
electrolytes and prostate specific antigen (PSA).
Hormonal indices
Hormonal indices evaluated were: oestradiol (E2), dihydro-
testosterone (DHT), androstenedione (A) and testosterone
(T). The method used for hormone measurement has
previously been published (Dowsett et al., 1989).
Blood was taken prior to and on days 1,2,3 and 7 after
commencing treatment with 4-OHA. Blood was then taken at
the monthly clinical assessments for endocrine measurements.
Wherever possible, blood samples were taken at the same
time of day on each occasion.
Objective response
Primary tumour volume Accurate measurement of tumour
volume was difficult due to the extensive nature of the
majority of the primary tumours causing marked prostatic
capsular distortion. This interfered with volume estimation
which was determined by the planimetric method. In 21
patients in which it was measured, the median tumour
volume was 37'ml (range 18-72). Fourteen patients under-
went volume estimation during treatment (ten at 3 months
and four at 6 months). There were no appreciable changes in
the values obtained during treatment.
Skeletal metastases All patients progressed with regards to
metastatic disease with no apparent improvements in isotope
bone scans and radiographs during treatment.
Haematological indices There were no improvements in
Symptomatic response haemoglobin or other indices during treatment.
This was assessed by reference to the ECOG scale as in the
preliminary study (Shearer et al., 1990) at monthly intervals.
A complete subjective response was defined as an ECOG
score of 0 on 2 consecutive occasions at least 4 weeks apart
and partial response as a reduction in ECOG score of greater
than 50% (Ponder et al., 1984).
Treatment
4-OHA was supplied by Ciba-Geigy Pharmaceuticals in vials,
each containing 250 mg of formulated microcrystalline
powder.
Each vial was reconstituted with 2 ml of saline before use.
Dosage used was 500mg as a single deep intra-muscular
injection on a weekly basis administered by a research nurse
at the patients home.
Results
Thirty patients were entered into the study. The age range
was 59-87 years (average 72). All had ECOG scores of at
least 9. Four had a baseline score of 10. Twenty seven (87%)
patients were taking narcotic analgesics. All patients were
noted to be taking some form of non-narcotic analgesic. All
had bony metastases, the most common sites being lumbar
spine, pelvis and ribs. None had soft tissue metastases.
Twenty eight patients (90%) had undergone an orchidectomy
as first-line treatment with a median duration of response of
12 months (range 2-43). Two patients received the LHRH
analogue, Goserelin, as first line therapy. Twenty patients
(65%) had received palliative radiotherapy before entry into
the study either in the form of single fraction or hemi-body
irradiation. Two had received steroids and one had been
given Strontium 89.
Prior to entry into the study, all patients were noted to
have low haemoglobin levels, indicative of the bone marrow
disease usually present in such patients. All had raised
alkaline and acid phosphatase levels representing extensive
bony metastatic disease.
Five patients (16%) were inevaluable for the following
reasons: One patient withdrew after the first treatment due to
deciding not to continue to attend for follow up, two patients
had not responded to first line endocrine therapy and were
therefore excluded from the analysis, two patients were tak-
ing cyproterone acetate (anti-androgen) at the start of the
study. The latter will be discussed further (see text).
Subjective response
Fifteen patients (60%) showed a complete subjective res-
ponse, mainly in the form ofpain relief and increased perfor-
mance. Three (12%) had a partial subjective response. Seven
(28%) did not respond. Fifteen (60%) had responded by visit
1 (4 weeks) and all responders by visit 2 (8 weeks). The
median duration of response was two visits (8 weeks).
Biochemical indices Electrolytes and liver function were
unaffected by 4-OHA. In ten patients (40%), alkaline phos-
phatase did not progress whilst in nine patients (36%), acid
phosphatase remained stable. PSA was measured in four
patients, before and during treatment with 4-OHA, using the
Hybritech kit. Laboratory reference range was 0-4ngml-'.
Pre-treatment levels were all markedly raised (284.4-
4576.69 ng ml ', mean 1492.7). At 3 months, two patients
had demonstrated a reduction in PSA although still demon-
strated high levels whilst two had further increases in PSA
from baseline.
Endocrine results
Oestradiol (Figure la) Serum levels of oestradiol (E2) were
measured in 23 patients. The pre-treatment range was
3.1-29 pmol l' (mean 13.6 ± 6.5 pmol I`, mean ± s.d.). E2
suppression was observed in 19 of 25 (76%) of patients and
appeared to be maximal by week 2 of treatment. The supp-
ression observed was statistically significant (P<0.001). In
four (16%) patients, there appeared to be no evidence of
suppression. However, there did not appear to be any corre-
lation between clinical response, tumour flare and E2 supp-
ression.
Testosterone (Figure lb) Testosterone (T) was measured in
14 patients. The pre-treatment range was 0.1-2.1 nmol I`
(mean 0.51 ± 0.56 nmol 1`). There was a small, statistically
significant, rise in testosterone levels (0.56 ± 0.48 nmol1-1,
P<0.05) during treatment. There was no correlation with
response or with tumour flare.
Dihydrotestosterone (Figure ic) Dihydrotestosterone (DHT)
was measured in 11 patients. The pre-treatment range was
0.1-0.73 nmol 1- (mean 0.25 ± 0.24 nmol 1`). Serum levels
rose during treatment (0.53 ± 0.81 nmol 1-1, P<0.05). There
was no correlation between response and DHT changes.
Androstenedione (Figure Id) Androstenedione (A) was
measured in 14 patients. Pre-treatment range was 0.21-
5.0 nmol I` (mean 1.4 ± 1.4 nmol I`). Serum levels rose
during treatment (1.9 ± 1.61 nmol 1', P<0.05). There did
not appear to be any correlation between response, tumour
flare and androstenedione changes on treatment.
Side effects
4-OHA was generally well tolerated by patients. In two
patients the dose was halved to 250 mg i.m. weekly due to
pain at the site of the injection.
Tumourflare Seventeen patients (68%) had a tumour flare,
three (12%) severe. The flare took the form of an increase in
bone pain, usually occurring 12-24 h after the first 4-OHA
injection. In the majority of cases, this flare was mild and
required a temporary increase in analgesia. The flare usually
subsided within 24-48 h. Two patients entered the trial, but
were subsequently excluded due to being on cyproterone
acetate at the start of the study. One of these patientsAROMATASE INHIBITION IN PROSTATIC CANCER 141
a
Oestradiol (E2) pmol 1-1
I I I I &y _1 L
2
1.8
1.6
1.4
1.2
1
0.8
H 0.6
0.4
0.2
C
-0.2
-0.4
28 56 70 0 1 2 3 4 5 6 7(a 14
Time (days)
b Testosterone (T) nmol I1-
Im- i. -
0 1 2 3 4 5 6 7 "' 14
Time (days)
5 dihydrotestosterone (DHT) nmol I-'
- 1
I I
0 1 2 3 4 5 6 7 '' 14
Time (days)
d Androstenedione (A) nmol 1-
4
2
-2
28 56 70 0 1 2 3 4 5 6 7 'I14 28 56 70
Time (days)
Figure 1 Effect of 4-OHA (500 mg i.m. weekly) on (a) serum oestradiol in pmol 1-l(b), serum testosterone in nmol 1V , (c), serum
5 a dihydrotestosterone in nmol l-I (d), serum androstenedione in nmols 1-' (s.d.). Mean values shown with 95% confidence limit
bars.
experienced a flare. The three patients in whom the flare was
severe, required a marked increase in analgesia and 1
required further palliative radiotherapy.
The endocrine studies did not indicate any correlation
between tumour flare and oestradiol suppression or changes
in androgen levels during treatment with 4-OHA.
Nausea and vomiting Two patients experienced nausea and
vomiting on commencing 4-OHA which was treated by con-
ventional anti-emetics. However most patients experienced
some degree of nausea prior to treatment, presumable related
to narcotic analgesia use.
Urticaria One patient experienced mild urticaria soon after
commencing 4-OHA. This responded to anti-histamines.
Vaso-vagal episode One patient collapsed immediately after
a 4-OHA injection. He rapidly recovered. This was thought
to be a vaso-vagal episode. This patient discontinued 4-OHA
treatment.
Discussion
The management of patients with advanced prostatic cancer
who have failed first line endocrine manoeuvres, such as
androgen deprivation, is difficult and is generally aimed at
the palliation of symptoms, usually pain. The patients
reported in this study all had heavily pre-treated end stage
advanced prostate cancer. The quality of subjective response,
in the form of increased performance and reduced pain relief,
was impressive. The absence of objective responses is not
surprising in this type of patient with widespread skeletal
metastatic tumour burden.
The tumour flare observed in a high proportion of the
patients in this study remains unexplained. The majority of
patients demonstrated a fall in E2 during treatment but flare
occurred in patients who did not demonstrate a fall in E2.
4-OHA is known to have weak androgenic properties (Brodie
et al., 1977) and this may be responsible for the flare. The
endocrine results indicate that, in some patients, small in-
creases in T, DHT and A occurred on treatment with 4-
OHA. The mechanism of this increase in androgen levels is
unknown. No such changes have been noted in post-
menopausal female patients with breast cancer (Dowsett et
al., 1989) but minor increases were noted in male volunteers
with intact gonadal function treated with 4-OHA orally
(Dowsett & Lloyd, 1990). In this latter study it was post-
ulated that a competition for catabolic routes of metabolism
between 4-OHA and endogenous androgens may be the
cause of the increase. There did not, however, appear to be
any correlation with changes in androgens and those patients
who experienced tumour flare. Cyproterone acetate did not
influence the development or course of the flare. It is possible
that one or more of the metabolites of 4-OHA are andro-
genic and responsible for the flare. 4-hydroxytestosterone is a
know metabolite in rhesus monkeys treated with 4-OHA
(Brodie et al., 1981b) but has not been demonstrated in
humans. We examined the urine samples of two patients who
experienced a tumour flare on 4-OHA by mass spectrometry
and HPLC. 4-OHT was not detected (Poon et al., unpub-
lished data). 4-OHT has been shown to bind strongly to the
rat androgen receptor (Houghton et al., unpublished data)
but whether it is acting as agonist or antagonist is not clear.
It is possible that oestradiol suppression reduces the and-
rogen receptor levels or interferes with their response to
androgens and 4-OHT/OHA. This may account for the flare
subsiding within 24-48 h.
The possibility that aromatase inhibitors may be of benefit
in patients with advanced prostate cancer stems from obser-
vations made during treatment of such patients with Ag.
Originally, it was thought that Ag was acting by reducing
adrenal androgens, a 'medical adrenalectomy'. However, it
was subsequently shown that any beneficial effects of Ag was
not due to this action (Dowsett et al., 1988). Ag is a potent
aromatase inhibitor and therefore it seemed important to test
a more selective aromatase inhibitor without the central ner-
vous system side effects of AG. 4-OHA is a steroidal
aromatase inhibitor which has been extensively investigated
in the treatment of women with advanced breast cancer
(Goss et al., 1984). Much data have been accrued concerning
the effects of such inhibitors in the female but little is known
concerning their effects in man. Our preliminary study
(Shearer et al., 1990) indicated that oestrogen suppression
occurred during treament with 4-OHA and it was considered
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that this may be responsible for the benefit observed. Oestro-
gens have attracted considerable interest in connection with
prostatic biology particularly in the pathogenesis of benign
prostatic hyperplasia (BPH) (Henderson et al., 1986). Several
lines of evidence suggest that oestrogens may be involved in
the development of BPH (Matzkin et al., 1991). Whether
oestrogens play a role in the development and progression of
prostatic carcinoma remains conjectural. We have conducted
parallel laboratory studies which have shown that the
aromatase enzyme does not appear to be present in either
benign or malignant prostatic tissue in vitro (Davies et al.,
1989). It has been reported that 4-OHA inhibits human
prostatic 5 a reductase (Zoppi et al., 1988) enzyme activity.
However, we have found that this inhibition is very weak in
human benign and malignant prostatic tissue in vitro (Davies
et al., 1989). This clinical study found no relationship
between subjective response and oestradiol suppression. The
mechanism of action of 4-OHA therefore remains unclear.
The beneficial effects of 4-OHA may be due to an action
unrelated to its aromatase inhibitory activity. Inhibition of
prostaglandin synthetase activity as a possible mode of action
by AG in patients with prostate cancer (Harris et al., 1983)
or a central action (Santen et al., 1981) has been suggested.
Whether this is the case in patients treated with 4-OHA is
unsubstantiated.
In conclusion, we have found 4-OHA to be effective in
palliating patients with advanced prostate cancer who have
failed all other palliative measures. The mechanism of action
of 4-OHA in such patients may be by suppressing oestradiol,
altering oestrogen related bone metabolism and hence reduc-
ing metastatic activity. Further work in this area would
appear worthwhile and may lead to further understanding of
the effects of oestrogens on prostatic biology and on metas-
tatic prostate cancer.
4-OHA was supplied by Ciba-Geigy Pharmaceuticals, Horsham. The
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